Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Quoc Truong

Hematology & Oncology Wichita, KS Medical Doctor

NPI 1518922814 CMS profile 250830

818 N Enmporia, Suite 403, Wichita, KS 67214

Open in the dashboard

General payments

$538,556

2,265 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$662 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Quoc Truong of Wichita, KS is reported in the CMS Open Payments database as having received $538,556 across 2,265 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $662 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $56,807 266
2024 General $62,915 298
2023 General $43,483 299
2022 General $81,505 335
2021 General $91,461 398
2020 General $57,440 260
2019 General $144,945 409

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Quoc Truong
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Quoc Truong were reported at $56,807. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Quoc Truong Hematology & Oncology median Middle half National median
2019 $144,945 $529 $121–$2,516 $163
2020 $57,440 $339 $82–$2,213 $114
2021 $91,461 $263 $49–$1,965 $132
2022 $81,505 $416 $103–$2,395 $149
2023 $43,483 $542 $125–$2,646 $160
2024 $62,915 $692 $141–$3,008 $164
2025 $56,807 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $135,339 191 payments
  2. Incyte Corporation $95,821 96 payments
  3. Celgene Corporation $51,216 106 payments
  4. Eisai Inc. $29,837 64 payments
  5. BeiGene USA, Inc. $21,009 31 payments
  6. Janssen Pharmaceuticals, Inc $20,983 27 payments
  7. Merck Sharp & Dohme Corporation $17,965 101 payments
  8. Jazz Pharmaceuticals Inc. $16,602 24 payments
  9. Janssen Biotech, Inc. $16,303 85 payments
  10. Daiichi Sankyo Inc. $16,144 61 payments
  11. Other $117,336 1,479 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $364,540 170 payments
  2. Consulting Fee $76,076 49 payments
  3. Food and Beverage $40,029 1,914 payments
  4. Travel and Lodging $31,210 88 payments
  5. Honoraria $24,725 17 payments
  6. Education $813 20 payments
  7. Long term medical supply or device loan $598 6 payments
  8. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $565 1 payment
Products named General payments · program years 2019–2025
  1. JAKAFI $91,633 82 payments
  2. IMFINZI $42,332 65 payments
  3. Lenvima $29,638 62 payments
  4. CALQUENCE $29,230 39 payments
  5. Abraxane $23,318 28 payments
  6. XARELTO $20,967 26 payments
  7. BRUKINSA $20,184 30 payments
  8. ENHERTU $16,585 28 payments
  9. ZEPZELCA $16,509 20 payments
  10. TAZVERIK $15,032 22 payments
  11. Other $181,595 2,275 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

2,219

Median for Hematology-Oncology: 604

Drug cost

$2,682,429

Median for Hematology-Oncology: $1,306,514

Branded share of claims

13.7%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lenalidomide Generic 62 $768,577
Imbruvica Ibrutinib Brand 24 $392,095
Ibrance Palbociclib Brand 23 $335,765
Brukinsa Zanubrutinib Brand 18 $257,209
Jakafi Ruxolitinib Phosphate Brand 21 $193,249
Besremi Ropeginterferon Alfa-2b-Njft Brand 12 $188,811
Rydapt Midostaurin Brand 11 $125,142
Venclexta Venetoclax Brand 13 $124,870
Ingrezza Valbenazine Tosylate Brand 13 $118,440
Lynparza Olaparib Brand 13 $110,493

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 236 billing codes

Paid by Medicare

$7,191,127

Of which drugs: $6,667,157

Medicare patients

1,273

Average age 74

Services billed

416,773

753 women, 520 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 56%
Arthritis 37%
Diabetes 34%
Ischemic heart disease 30%
Chronic kidney disease 28%
Depression 25%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 56 29,800 $1,328,502
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 20 14,760 $579,084
Injection, nivolumab, 1 mg J9299 Office 20 19,640 $484,289
Injection, durvalumab, 10 mg J9173 Office 13 4,872 $310,755
Injection, atezolizumab, 10 mg J9022 Office 12 4,008 $268,156
Injection, denosumab, 1 mg J0897 Office 72 11,640 $237,279
Injection, eflapegrastim-xnst, 0.1 mg J1449 Office 45 10,824 $226,792
Injection, trastuzumab, 10 mg J9355 Office 15 3,420 $212,580
Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg Q5129 Office 25 4,150 $203,955
Injection, romiplostim, 10 micrograms J2796 Office 14 1,979 $152,788

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 93 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
$20,452 — —
IMFINZI
$6,777 — 4,872
TAGRISSO
$5,305 — —
CALQUENCE
$3,090 — —
KEYTRUDA
$2,506 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 93 with Patron

Records

2,265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record